Baseline and clinical characteristics of adults initiating ART according to hepatitis B and hepatitis C status in Phnom Penh, Cambodia 2003–2012 (N = 3089).

<p>ART: antiretroviral treatment; NNRTI: non-nucleoside reverse transcriptase inhibitor; NRTI: nucleoside reverse transcriptase inhibitor; WHO: world health organization.</p>a<p>There were 3089 individuals included in the study; since there were 12 patients with both HepB and Hep C coinfection, the total adds up to 3101.</p

CD4 evolution after initiation of antiretroviral treatment according to co-infection with hepatitis B virus (upper graph) and hepatitis C virus (lower graph).

<p>CD4 evolution after initiation of antiretroviral treatment according to co-infection with hepatitis B virus (upper graph) and hepatitis C virus (lower graph).</p

Kaplan-Meier graph showing cumulative mortality after initiation of antiretroviral treatment according to co-infection with hepatitis B virus (upper graph) and hepatitis C virus (lower graph).

<p>Kaplan-Meier graph showing cumulative mortality after initiation of antiretroviral treatment according to co-infection with hepatitis B virus (upper graph) and hepatitis C virus (lower graph).</p

Effect of hepatitis B or C co-infection on the risk for severe NNRTI-related toxicity after ART initiation in Phnom Penh, Cambodia, 2003–2012 (N = 3089).

a<p>95% confidence interval given in parenthesis.</p>b<p>Adjusted for age, gender, baseline CD4 count, baseline body weight, type of NNRTI (efavirenz vs nevirapine), baseline liverfunction tests (serum alanine aminotransferase).</p>c<p>Adjusted for age, gender, baseline CD4 count, type of NNRTI (efavirenz vs nevirapine).</p><p>aOR: adjusted odds ratio; NNRTI: non-nucleoside reverse transcriptase inhibitor.</p

Estimated effect of hepatitis B or C co-infection on CD4 count change after initiation of antiretroviral treatment.

a<p>Linear mixed effects model. The coefficient assesses the effect of the covariate (hepatitis B or C) on the slope (or change) of the CD4 count (unit: cells/μL/year); 95% confidence interval given in parentheses.</p>b<p>The multivariate model included the following potential confounding factors: age, gender, baseline CD4 count, baseline hemoglobin, baseline body weight, baseline WHO clinical stage, type of NNRTI or NRTI used.</p

Evolution of liver function tests (ALT) after initiation of antiretroviral treatment according to Hepatitis B (upper graph) and Hepatitis C (lower graph).

<p>Evolution of liver function tests (ALT) after initiation of antiretroviral treatment according to Hepatitis B (upper graph) and Hepatitis C (lower graph).</p